Published in Cancer Res on March 01, 1988
ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol (2000) 2.53
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A (2006) 2.23
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer (1991) 1.37
The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer (1991) 1.35
Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol (2006) 1.34
Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer (1991) 1.33
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J (1991) 1.33
c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer (1991) 1.30
Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells. Mol Cell Biol (1990) 1.26
ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer (2000) 1.24
An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer (1989) 1.23
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer (1993) 1.21
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
Breast cancer and a proto-oncogene. BMJ (1989) 1.13
Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol (1997) 1.10
Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer (1990) 1.09
Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol (1992) 1.09
Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol (2010) 1.08
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer (2006) 1.07
An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol (1993) 1.06
C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer (1990) 1.04
Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res (2010) 1.03
Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br J Cancer (1991) 1.01
Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Pathol (1990) 0.99
The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium. Carcinogenesis (2007) 0.98
c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol (1992) 0.98
Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659----Glu659). EMBO J (1990) 0.96
E3 ubiquitin ligases in ErbB receptor quantity control. Semin Cell Dev Biol (2010) 0.96
c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer (1989) 0.96
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer (1995) 0.95
E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma. Br J Cancer (1996) 0.91
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat (2008) 0.91
Multiple cis- and trans-acting elements involved in regulation of the neu gene. Mol Cell Biol (1990) 0.90
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs (2008) 0.89
Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci U S A (1992) 0.88
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Mol Pathol (2001) 0.87
Primary medical treatment in breast cancer. BMJ (1991) 0.84
Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer (1994) 0.83
In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Mol Cell Proteomics (2014) 0.83
Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer (1993) 0.83
Specific detection of c-erbB-2 mRNA expression in gastric cancers by the polymerase chain reaction following reverse transcription. Br J Cancer (1992) 0.82
Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med (2010) 0.82
Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. Am J Pathol (1991) 0.82
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer. Breast Cancer (Auckl) (2016) 0.82
p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia (2003) 0.81
A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer (1996) 0.80
Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res (1996) 0.80
Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive. Mol Cell Biol (2016) 0.80
Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer (1990) 0.80
c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer (1992) 0.80
Development of a new metastatic human breast carcinoma xenograft line. Br J Cancer (1998) 0.80
Therapeutic monoclonal antibodies in oncology. J R Soc Med (2005) 0.79
Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br J Cancer (2005) 0.79
HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES. Proc S Dak Acad Sci (2007) 0.79
Prognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer. Br J Cancer (1993) 0.79
The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol (2014) 0.78
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol (2016) 0.77
A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells. Neoplasia (2000) 0.77
Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models. NMR Biomed (2012) 0.76
Inducible Mouse Models for Cancer Drug Target Validation. J Cancer Prev (2016) 0.75
Biological indices in the assessment of breast cancer. Clin Mol Pathol (1995) 0.75
Retracted Cancer biomarker HER-2/neu in breast cancer in Indian women. Breast Cancer (Dove Med Press) (2011) 0.75
Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol (2005) 0.75
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature (1983) 8.60
Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 8.23
Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science (1993) 7.86
Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A (1982) 7.34
Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 6.55
Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science (1986) 6.10
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
Autophosphorylation sites on the epidermal growth factor receptor. Nature (1984) 5.11
Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature (1998) 5.04
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat Cell Biol (1999) 4.76
Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci (1997) 4.52
Hormone-responsive expression of an endogenous proviral gene of mouse mammary tumor virus after molecular cloning and gene transfer into cultured cells. Proc Natl Acad Sci U S A (1981) 4.30
Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J (1994) 4.03
Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein. Cell (1985) 4.02
The complete primary structure of protein kinase C--the major phorbol ester receptor. Science (1986) 4.02
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J (1996) 3.99
The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J (1996) 3.78
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol (1999) 3.47
Subfragments of the large terminal repeat cause glucocorticoid-responsive expression of mouse mammary tumor virus and of an adjacent gene. Proc Natl Acad Sci U S A (1983) 3.42
Purification of the fusion protein of Sendai virus: analysis of the NH2-terminal sequence generated during precursor activation. Proc Natl Acad Sci U S A (1978) 3.42
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO J (1996) 3.41
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J (1994) 3.32
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J (1995) 3.19
P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09
Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol (1996) 3.08
Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development (1992) 3.04
A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem (1982) 3.04
PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J (1994) 3.02
Active site and complete sequence of the suicidal methyltransferase that counters alkylation mutagenesis. Proc Natl Acad Sci U S A (1985) 3.01
Large and small tumor antigens from simian virus 40 have identical amino termini mapping at 0.65 map units. Proc Natl Acad Sci U S A (1978) 3.00
Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature (1988) 2.99
Studies on the primary structure of the influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1975) 2.88
Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J (1988) 2.82
Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A (1995) 2.79
Regulation of imaginal disc cell size, cell number and organ size by Drosophila class I(A) phosphoinositide 3-kinase and its adaptor. Curr Biol (1999) 2.76
Functional interactions between Stat5 and the glucocorticoid receptor. Nature (1996) 2.64
ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol (2000) 2.53
Long terminal repeats of endogenous mouse mammary tumour virus contain a long open reading frame which extends into adjacent sequences. Nature (1982) 2.48
Hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties. Proc Natl Acad Sci U S A (1985) 2.47
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet (1987) 2.44
ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem (1999) 2.41
Expression of a platelet-derived growth factor-like protein in simian sarcoma virus transformed cells. Science (1983) 2.41
Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res (1986) 2.38
Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res (1993) 2.35
Tyr721 regulates specific binding of the CSF-1 receptor kinase insert to PI 3'-kinase SH2 domains: a model for SH2-mediated receptor-target interactions. EMBO J (1992) 2.29
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
Number and location of mouse mammary tumor virus proviral DNA in mouse DNA of normal tissue and of mammary tumors. J Virol (1980) 2.25
New mammary epithelial and fibroblastic cell clones in coculture form structures competent to differentiate functionally. J Cell Biol (1989) 2.24
Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci U S A (1987) 2.23
Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem (1985) 2.22
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Glucocorticoid receptors recognize DNA sequences in and around murine mammary tumour virus DNA. EMBO J (1982) 2.21
Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase. Cell (1993) 2.20
Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences. EMBO J (1988) 2.19
Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity (1997) 2.17
Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol (1995) 2.13
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Purification and properties of porcine platelet-derived growth factor. EMBO J (1984) 2.06
Purification and characterization of vaccinia virus growth factor. Cell (1985) 2.06
Activated phosphoinositide 3-kinase associates with membrane skeleton in thrombin-exposed platelets. J Biol Chem (1992) 2.04
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene (2000) 2.01
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J (1995) 2.00
STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood (1996) 1.99
Purification to homogeneity of protein kinase C from bovine brain--identity with the phorbol ester receptor. EMBO J (1984) 1.97
Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol (1999) 1.96
Beta-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor. Mol Cell Biol (1991) 1.93
ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol (2000) 1.92
Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett (1997) 1.91
mRNA complexity and egg white protein mRNA content in mature and hormone-withdrawn oviduct. Cell (1977) 1.91
Mammary tumor induction loci in GR and DBAf mice contain one provirus of the mouse mammary tumor virus. Cell (1981) 1.89
Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci U S A (1995) 1.89
ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol (1998) 1.88
Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem (1996) 1.88
Structure of an SH2 domain of the p85 alpha subunit of phosphatidylinositol-3-OH kinase. Nature (1992) 1.86
Characterization of endogenous and exogenous mouse mammary tumor virus proviral DNA with site-specific molecular clones. J Virol (1980) 1.80
Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150.Ptdins 3-kinase complex. J Biol Chem (1997) 1.78
Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J (1993) 1.76